Growth and endocrinopathies among children with β-Thalassemia major treated at Dubai Thalassemia centre

BMC Pediatrics

Table 4 Comparing height velocity measured in two consecutive years by other parameters

	N	Normal in both years		Delayed in One/two years		Chi-square	p-value
	N	n	%	n	%	Chi-square	p-value
Age group
2–9	25	6	24.0	19	76.0	0.048	0.826
10–18	37	8	21.6	29	78.4	0.048	0.826
Gender
Male	30	11	36.7	19	63.3	6.597	*0.010*
Female	32	3	9.4	29	90.6	6.597	*0.010*
Nationality
UAE	30	9	30.0	21	70.0	3.487	0.175
Arabs	9	3	33.3	6	66.7
Non-Arabs	21	2	9.5	19	90.5
DFO (Deferoxamine) Chelation Drug
No	50	12	24.0	38	76.0	0.298	0.717
Yes	12	2	16.7	10	83.3	0.298	0.717
DFP (Deferiprone) Chelation Drug
No	59	13	22.0	46	78.0	0.209	0.543
Yes	3	1	33.3	2	66.7	0.209	0.543
DFX (Deferasirox) Chelation Drug
No	15	3	20.0	12	80.0	0.075	1.000
Yes	47	11	23.4	36	76.6	0.075	1.000

ISSN: 1471-2431